XOMA Corp. Goes Down Heavily As Main Drug Fails Challenge Print E-mail
By Josh Gee   
Thursday, 23 July 2015 19:01
XOMA Corp. (NASDAQ:XOMA) crashed down investor dreams. The Berkeley, CA-based biotech firm stated that Phase III study of gevokizumab in patients with Behçet's disease uveitis was unsuccessful.
Read more...
 
Novavax, Inc. Reports Good Top-Line Data from Phase 1 Ebola Vaccine Trial Print E-mail
By David Fowler   
Tuesday, 21 July 2015 15:16
Clinical stage vaccine firm Novavax, Inc. (NASDAQ:NVAX) which is focused on discovery as well as commercialization of recombinant nanoparticle vaccines has confirmed good top-line data from Phase 1 clinical trial of Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M as part of World Health Organization’s Fifth Teleconference on Ebola Vaccine Clinical Trials.
Read more...
 
Exelixis, Inc. Jumps 51% On Meteroric METEOR Results Print E-mail
By David Fowler   
Monday, 20 July 2015 14:44
Exelixis, Inc. (NASDAQ:EXEL) has confirmed positive top-line results resulting out of initial analysis of METEOR, phase 3 pivotal trial that compares cabozantinib to everolimus in more than 658 patients suffering from metastatic renal cell carcinoma.
Read more...
 
C2N and Abbvie Inc. Confirm FDA Orphan Drug Designation Of C2n-8e12 For Treating Progressive Supranuclear Palsy Print E-mail
By David Fowler   
Friday, 17 July 2015 16:00
C2N Diagnostics and AbbVie Inc. (NYSE:ABBV) have confirmed that U.S. Food and Drug Administration has given approval for the investigational recombinant humanized anti-tau antibody.
Read more...
 
Radius Health Announces Pre-clinical Data for Investigational Drug Print E-mail
By David Fowler   
Thursday, 16 July 2015 18:48
Biopharmaceutical firm Radius Health Inc. (NASDAQ:RDUS) has confirmed early yet promising preclinical data demonstrating that the investigational drug RAD1901 along with CDK4/6 inhibitors like Pfizer's palbociclib and mTOR inhibitors, such as Novartis' everolimus was able to reduce tumors.
Read more...
 
Anacor Hits All Time High After Skin Ointment Success Print E-mail
By Josh Gee   
Monday, 13 July 2015 15:45
Anacor Pharmaceuticals Inc. (NASDAQ:ANAC)’s skin ointment has found success in studies taking it closer to having a potential blockbuster and it may increase expectations which may be taken over.
Read more...
 
Dyax Gets FDA Breakthrough Therapy Designation for DX-2930 Print E-mail
By Marilyn Mullen   
Tuesday, 07 July 2015 15:06
Dyax Corp. (NASDAQ:DYAX) has confirmed that U.S. Food and Drug Administration has given approval to Breakthrough Therapy designation for investigation of DX-2930 for hereditary angioedema.
Read more...
 
Invivo Therapeutics confirms huge improvement of Second and Third Patients done with Neuro-Spinal Scaffold Print E-mail
By David Fowler   
Monday, 06 July 2015 16:34
Invivo Therapeutics Holdings Corp. (NASDAQ:NVIV) has confirmed an update for one-month post-implant for third study patient as well as six-month post-implant update for second study patient in present pilot trial of investigational Neuro-Spinal Scaffold in patients having acute spinal cord injury.
Read more...
 
Sarepta Therapeutics Inc. NDA Submission to FDA for Eteplirsen for treating Duchenne Muscular Dystrophy Print E-mail
By Josh Gee   
Monday, 29 June 2015 19:34
Developer of RNA-targeted therapeutics Sarepta Therapeutics Inc. (NASDAQ:SRPT) has confirmed completion of rolling submission of New Drug Application to United States Food and Drug Administration for eteplirsen on June 26, 2015.
Read more...
 
Celladon Corp. Shares Slump 40% on Mydicar development Print E-mail
By Marilyn Mullen   
Friday, 26 June 2015 17:19
Celladon Corp. (NASDAQ:CLDN) plunged over 40% to $1.31 and made a record low of $1.24 earlier in the session after the company revealed its plans of suspending more research on developing its MYDICAR  program as well as its other pre-clinical programs which include Stem Cell Factor  gene therapy as well as SERCA2b small molecule programs.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 2 of 12

Newsletter